BML 4.98 Decreased By ▼ -0.03 (-0.6%)
BOP 13.11 Increased By ▲ 0.03 (0.23%)
CNERGY 7.18 Increased By ▲ 0.06 (0.84%)
CPHL 87.50 Increased By ▲ 0.05 (0.06%)
DCL 14.46 Increased By ▲ 0.12 (0.84%)
DGKC 171.50 Increased By ▲ 0.74 (0.43%)
FCCL 46.79 Increased By ▲ 0.03 (0.06%)
FFL 16.03 Increased By ▲ 0.21 (1.33%)
GCIL 26.71 Decreased By ▼ -0.16 (-0.6%)
HUBC 146.82 Increased By ▲ 2.64 (1.83%)
KEL 5.33 Increased By ▲ 0.26 (5.13%)
KOSM 6.56 Decreased By ▼ -0.13 (-1.94%)
LOTCHEM 20.51 Decreased By ▼ -0.08 (-0.39%)
MLCF 85.45 Increased By ▲ 0.72 (0.85%)
NBP 122.70 Increased By ▲ 0.88 (0.72%)
PAEL 43.90 Increased By ▲ 0.44 (1.01%)
PIAHCLA 22.45 Increased By ▲ 0.16 (0.72%)
PIBTL 9.00 Increased By ▲ 0.07 (0.78%)
POWER 13.99 Decreased By ▼ -0.02 (-0.14%)
PPL 168.75 Decreased By ▼ -1.19 (-0.7%)
PREMA 42.87 Decreased By ▼ -0.52 (-1.2%)
PRL 33.37 Increased By ▲ 0.26 (0.79%)
PTC 23.90 Decreased By ▼ -0.36 (-1.48%)
SNGP 118.62 Decreased By ▼ -1.02 (-0.85%)
SSGC 46.13 Increased By ▲ 0.58 (1.27%)
TELE 8.23 Increased By ▲ 0.15 (1.86%)
TPLP 10.45 Decreased By ▼ -0.02 (-0.19%)
TREET 24.06 Increased By ▲ 0.09 (0.38%)
TRG 58.41 Increased By ▲ 0.36 (0.62%)
WTL 1.56 Increased By ▲ 0.04 (2.63%)
BR100 13,804 Increased By 173.2 (1.27%)
BR30 40,095 Increased By 244.2 (0.61%)
KSE100 136,198 Increased By 1898.6 (1.41%)
KSE30 41,421 Increased By 607 (1.49%)

Merck & Co Inc and partner Ridgeback Biotherapeutics said on Friday six lab studies showed their experimental oral COVID-19 drug molnupiravir was active against the fast-spreading Omicron variant.

The data evaluated the antiviral activity of molnupiravir and other COVID-19 antiviral agents against COVID-19 variants of concern. Molnupiravir is yet to be studied against Omicron in human studies, the companies said.

Molnupiravir and a rival oral pill from Pfizer Inc were authorized in the United States in December and are considered as important tools against Omicron.

Merck expects COVID-19 pill molnupiravir to be effective against Omicron

Pfizer said in December lab data suggested its drug Paxlovid retained its effectiveness against Omicron.

Merck said earlier this month its pill has a mechanism that can work against Omicron and any other variant.

Molnupiravir has been authorized for use in more than 10 countries, including the United States, United Kingdom and Japan.

Comments

Comments are closed.